Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA12 | O43570 | 4/20 | 0.57 |
| ▸ | CA7 | P43166 | 4/20 | 0.57 |
| ▸ | CA9 | Q16790 | 4/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.57 |
| ▸ | XDH | P47989 | 2/20 | 0.57 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632067 | 0.88 | CA1 (0.57) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15947258 | 0.84 | CA12 (0.45) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1092347 | 0.83 | PKM (0.51) | ALDH1A1KDM4EHSD17B10MAPTMEN1 | |
| SCHEMBL4404364 | 0.83 | CA12 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3373567 | 0.82 | CA12 (0.67) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7893012 | 0.80 | CA12 (0.65) | CA1CA2CA12CA7CA9 | |
| SCHEMBL10907964 | 0.79 | ALDH1A1 (0.55) | CA1CA2CA12CA7CA9 | |
| SCHEMBL6478663 | 0.78 | XDH (0.57) | CA1CA2CA12CA7CA9 | |
| SCHEMBL20766302 | 0.77 | GAA (0.55) | HKDC1CCR6HPGDALDH1A1LMNA | |
| SCHEMBL15657532 | 0.76 | CA1 (0.59) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| EP-1926730-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007030061-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030061-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
| CN-1119182-A | Insecticidal N,N'-disubstituted-N,N'-diacylhydrazines | ROHM & HAAS (US) | 1996-03-27 | — | — | CN | disclosed |
| EP-0693486-A1 | Insecticidal N-substituted-N'-(optionally substituted)-N,N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5482962-A | Insecticidal N,N'-disubstituted-N-N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR10 | CA1 4643/4885CA2 3690/4885CA12 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.